{"title":"来那度胺(REVLIMID°)治疗未经治疗的多发性骨髓瘤。","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In an unblended trial in 1623 multiple myeloma patients, treatment with lenalidomide + dexamethasone until disease progression appeared to prolong survival by a few months more than with the thalidomide + melphalan + prednisone combination given for 18 months, but serious adverse effects were more frequent.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"25 176","pages":"263-264"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"lenalidomide (REVLIMID°) in untreated multiple myeloma.\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In an unblended trial in 1623 multiple myeloma patients, treatment with lenalidomide + dexamethasone until disease progression appeared to prolong survival by a few months more than with the thalidomide + melphalan + prednisone combination given for 18 months, but serious adverse effects were more frequent.</p>\",\"PeriodicalId\":35983,\"journal\":{\"name\":\"Prescrire International\",\"volume\":\"25 176\",\"pages\":\"263-264\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prescrire International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescrire International","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
lenalidomide (REVLIMID°) in untreated multiple myeloma.
In an unblended trial in 1623 multiple myeloma patients, treatment with lenalidomide + dexamethasone until disease progression appeared to prolong survival by a few months more than with the thalidomide + melphalan + prednisone combination given for 18 months, but serious adverse effects were more frequent.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
